Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28330663 | 1.00 | PTGDR2 (0.58) | PTGDR2TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL1331642 | 0.89 | SMN1; SMN2 (0.47) | PTGDR2TSHRSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL20587837 | 0.88 | TSHR (0.53) | PTGDR2TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL30100272 | 0.88 | TSHR (0.53) | PTGDR2TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL1332563 | 0.88 | TSHR (0.53) | PTGDR2TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL1331643 | 0.88 | PTGDR2 (0.54) | PTGDR2 | |
| SCHEMBL27849129 | 0.84 | PTGDR2 (0.51) | PTGDR2TTRMCL1 | |
| SCHEMBL1753418 | 0.84 | PTGDR2 (0.76) | PTGDR2TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL1332548 | 0.81 | PTGDR2 (0.71) | PTGDR2TSHRPTGDR | |
| SCHEMBL4015627 | 0.81 | PTGDR2 (0.55) | PTGDR2TSHRHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394986-B2 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (GB) | 2013-03-12 | — | — | US | claimed |
| US-20110281898-A1 | PHENOXIACETIC ACID DERIVATIVES | ASTRAZENECA AB | 2011-11-17 | — | — | US | claimed |
| US-8003703-B2 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | claimed |
| EP-1660431-B1 | PHENOXYACETIC ACID DERIVATIVES | ASTRAZENECA AB (SE) | 2009-04-01 | — | — | EP | claimed |
| JP-2007502806-A | — | — | 2007-02-15 | — | — | JP | claimed |
| US-20060293352-A1 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | US | claimed |
| EP-1660431-A2 | PHENOXYACETIC ACID DERIVATIVES | Astrazeneca AB (SE) | 2006-05-31 | — | — | EP | claimed |
| WO-2005018529-A2 | PHENOXIACETIC ACID DERIVATIVES | ASTRAZENECA AB (SE) | 2005-03-03 | — | — | WO | claimed |
| US-20250228870-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS | ASTRAZENECA AB (SE) | 2025-07-17 | — | — | US | disclosed |
| EP-4548972-A2 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | AstraZeneca AB (SE) | 2025-05-07 | — | — | EP | disclosed |
| EP-3744714-B1 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2025-01-15 | — | — | EP | disclosed |
| US-20240336582-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | ASTRAZENECA AB (SE) | 2024-10-10 | — | — | US | disclosed |
| US-12054465-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2024-08-06 | — | — | US | disclosed |
| US-20240132455-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | ASTRAZENECA AB (SE) | 2024-04-25 | — | — | US | disclosed |
| US-8003703-B2 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| US-8003703-B2 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| EP-1660431-B1 | PHENOXYACETIC ACID DERIVATIVES | ASTRAZENECA AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| US-20060293352-A1 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | US | disclosed |
| EP-1660431-A2 | PHENOXYACETIC ACID DERIVATIVES | Astrazeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005018529-A2 | PHENOXIACETIC ACID DERIVATIVES | ASTRAZENECA AB (SE) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132455-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | PTGDR2 1586/4885TSHR 4180/4885HTR2A 3152/4885 |
| US-20060293352-A1 | Phenoxiacetic acid derivatives | HRH2, HRH1, HCAR2 | PTGDR2 13/4885TSHR 655/4885HTR2A 75/4885 |
| US-12054465-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | PTGDR2 1586/4885TSHR 4180/4885HTR2A 3152/4885 |
| US-20240336582-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | PTGDR2 1586/4885TSHR 4180/4885HTR2A 3152/4885 |
| US-20250228870-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS | DPEP1, TPP1, DPP9 | PTGDR2 1659/4885TSHR 4357/4885HTR2A 3500/4885 |
| US-20110281898-A1 | PHENOXIACETIC ACID DERIVATIVES | HIF1A, HPD, HIF1AN | PTGDR2 256/4885TSHR 1766/4885HTR2A 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.